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Abstract
Background—Cancer diagnosis has the potential to overshadow patients’ general medical care
needs. This study examined changes in general medical care among elderly patients with
colorectal cancer (CRC), from before diagnosis through long-term survival.
Methods—This longitudinal cohort study used 1993 to 1999 Surveillance, Epidemiology, and
End Results and 1991 to 2001 Medicare claims data for 22,161 patients with stage 0 to 3 CRC and
81,669 controls aged 67 to 89 years. Outcomes were preventive services (influenza vaccination,
mammography) and, among diabetics, HgbA1c and lipid testing in the phase before diagnosis, the
phase after initial treatment, the surveillance phase, and the survival care phase. Logistic
regression provided adjusted relative risks of care receipt for patients with stage 0 to 1 cancer,
stage 2 to 3 cancer, and no cancer.
Results—In the phase before diagnosis through the surveillance phase, patients with stage 0 to 1
CRC had the highest annual preventive service rates. Patients with stage 2 to 3 CRC made
substantial gains in preventive service use, especially mammography, after diagnosis (influenza
vaccination, 46.4% before diagnosis to 50.2% after initial treatment; mammography, 31.4% before
diagnosis to 40.2% after initial treatment) but not in diabetes care (eg, HgbA1c, 53.4% before
diagnosis to 54.9% after initial treatment).
Conclusions—CRC diagnosis seems to facilitate receipt of preventive services but not diabetes
care for elderly, later-stage patients. Additional strategies such as strengthening partnerships
between cancer patients, primary care physicians, and cancer care physicians are needed to
improve care for a chronic disease like diabetes.
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Approximately 70% of all cancer patients are aged ≥65 years and enter the cancer care
system with a broad range of medical conditions and preventive care needs.1–4 However,
cancer diagnosis has the potential to overshadow these general medical care needs. Several
studies suggest that addressing cancer patients’ general medical care can have an important
impact on survival.5–10 Higher mortality among black patients who are receiving cancer
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treatment comparable to that being received by white patients is largely related to deaths
from other conditions.5 Influenza vaccination receipt by patients with advanced-stage
colorectal cancer (CRC) has been associated with increased survival.6 Beyond survival,
Ramsey et al11 have demonstrated that noncancer comorbidity is the strongest predictor of
quality of life for most CRC survivors.
Relatively little research has been published about general medical care among cancer
patients. Earle and Neville12 found that 5-year CRC survivors received less preventive and
chronic disease care than noncancer patients matched on demographics and geography.
Lower influenza vaccination rates have been found among elderly patients with advanced-
stage CRC in chemotherapy compared with their elderly noncancer counterparts.6
Conversely, Snyder et al13 found increases in influenza vaccination but decreases in
mammography and cervical cancer screening in the 5 years after initial treatment among
patients with stage 1 to 3 CRC. However, none of these studies examined whether there was
a change in these patients’ receipt of general medical care services before and after cancer
diagnosis, nor did they compare cancer patients’ general medical care service receipt to that
of a control population.
This study builds on prior research by examining receipt of preventive and diabetes care
among elderly cancer and noncancer patients from the year before diagnosis through 3
cancer care phases: after initial treatment, surveillance, and long-term survival. We chose
diabetes because it is a common chronic medical condition with growing prevalence and
recommended diabetes care includes testing measurable by claims data. We hypothesized
that cancer diagnosis would be associated with a decline in receipt of preventive and
diabetes care that recovered as the time from diagnosis lengthened. This research
specifically addresses the Institute of Medicine’s call for increased attention to the quality of
care for cancer survivors.14
Methods
Data Sources
This study used the Surveillance, Epidemiology, and End Results (SEER) cancer registry
data linked with Medicare claims to identify cancer patients, and Medicare claims from the
annual 5% random sample of Medicare beneficiaries without cancer who resided in SEER
registry areas to identify controls.15 SEER data include patient demographics and cancer
type and stage. Medicare data include enrollment dates, health maintenance organization
membership, patient demographics and, for fee-for-service beneficiaries, new billed claims
that include diagnoses, tests, and procedures provided in hospitals, physician offices, and
clinics. The American Medical Association’s (AMA) Physician Masterfile data linked to the
Medicare claims provided physician specialty.
Study Population and Care Phases
Cancer patients had CRC in stages 0 to 3 reported between 1993 and 1999 and were 67 to 89
years old at diagnosis (n = 64,410). Sequentially excluded were individuals missing
diagnosis month (n = 114), those with a simultaneous stage 4 cancer (n = 244), those with
atypical histology (n = 284), and those diagnosed at autopsy (n = 108). Noncancer controls,
made up of the complete 5% random sample of all Medicare beneficiaries who lived in
SEER registry areas between 1993 and 1999, were randomly assigned a pseudodiagnosis
(from here on called “diagnosis”) month and year between January 1, 1993, and December
31, 1999, so that, like cancer patients, they had an anchor date from which to measure study
variables and care phases. The 161,115 noncancer controls who were 67 to 89 years old at
the assigned diagnosis date were included. Because we wanted to examine the association
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between a primary CRC diagnosis and receipt of general medical care, and because
additional cancer diagnoses might influence receipt of general medical care, we excluded
patients with additional SEER cancer diagnoses through 1999 (n = 13,989).
We defined 5 care phases for the study (Figure 1): before diagnosis (13 months before 1
month prior to the diagnosis month); washout (one month before through the fifth month
after the diagnosis month); after initial treatment (the year after washout); surveillance (2 to
4 years after washout); and survival (5 to 7 years after washout). We also gathered data in
the year before the phase before diagnosis to define pre-existing comorbidity, the number of
hospitalizations, and diabetes diagnosis. We required continuous enrollment in fee-for-
service parts A and B Medicare from the year before the phase before diagnosis through the
phase after initial treatment (resulting in exclusion of 27,510 cases and 79,446 controls).
Based on SEER/Medicare data availability, cases (n = 22,161) and controls (n = 81,669)
with diagnoses starting in February 1993 were included.
Study individuals contributed at least 2 data years (before diagnosis and after initial
treatment) and up to 8 data years (Table 1). Observation years with evidence of metastatic
disease (eg, ablation of liver lesion; see Appendix for codes) or recurrence treatment (ie,
chemotherapy and radiation administration; see Appendix for codes) were censored, as were
all subsequent years, because we surmised that recurrence or metastasis would decrease both
screening and monitoring of chronic disease. The average number of study years varied
significantly by cancer diagnosis and stage: 4.7 for controls, 4.4 for patients with stage 0 to 1
CRC, and 4.0 for patients with stage 2 to 3 CRC.
Outcome Variables
We measured 2 types of noncancer care: (1) preventive care (see Appendix for codes),
specifically mammography for women ages 67 to 74 years (n = 23,982) and influenza
vaccination; and (2) diabetes care as an example of chronic disease care, evaluating
glycosylated hemoglobin (HgbA1c) and lipid test measurements (see Appendix for codes)
among diabetics (n = 11,858). These measures were standard, guideline-recommended care
for older adults at the time of this study.16,17 Individuals with diabetes had one inpatient or 2
outpatient International Classification of Diseases, Ninth Revision, Clinical Modification,
diagnosis codes indicating diabetes in the year before prediagnosis (250.XX). Because
influenza vaccination was not a Medicare-covered service until May 1993, we allowed a 7-
month ramp-up and included only individuals with a phase before diagnosis year starting in
January 1994 (n = 73,421) in those analyses.
Independent Variable of Interest
Our independent variable of interest was CRC diagnosis status. Initial analyses identified
substantial differences in noncancer care between early-stage (stages 0 and 1) and later-stage
(stages 2 and 3) cancers, so we separated these groups.
Covariates
Time-independent covariates included patient sex; race (white, black, Hispanic, Asian, or
other); ZIP code–based median annual household income in the diagnosis year, ZIP code–
based percent of the population ≥25 years old who were high school graduates in the
diagnosis year; and reason for initial Medicare entitlement (disability or end-stage renal
disease vs age ≥65). The 2000 census provided the ZIP code–based variables. Time-
dependent variables included age at the observation year’s start (67 to 69 years, 70 to 74
years, 75 to 79 years, and 80 to 89 years); the number of hospitalizations during the year
before observation (0, 1, 2, 3, 4, ≥5); the number of visits to noncancer care physicians
during the observation year; the number of visits to cancer care physicians (general or
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colorectal surgeon, medical oncologist, radiation oncologist) during the observation year;
and comorbidity during the year before observation (using the National Cancer Institute’s
combined comorbidity index specific to CRC patients18). We identified cancer and
noncancer care physicians using linked data about primary specialty, secondary specialty,
and board certification from the 1993, 1997, and 2002 AMA Physician Masterfiles. When
AMA Physician Masterfile data were missing, we used the specialty code from the Medicare
claims file.
Analysis
We compared the characteristics of the 3 study groups from which our study samples were
drawn (patients with stage 0 to 1 CRC, patients with stage 2 to 3 CRC cases, and controls) in
the phase before diagnosis. We calculated unadjusted annual rates of receipt of preventive
and diabetes services by group in each phase before diagnosis, after initial treatment,
surveillance, and survival phase year; we then tested for trends in receipt of these services
within each of the 3 study groups over the 8 observation years and for differences in trends
between our 3 study groups using the general estimating equation (GEE) approach with a
logit link, using year, study group, and their interaction terms in the models. We used GEE
with an unstructured correlation matrix to account for clustering by individual because each
could contribute up to 8 data years. We excluded the washout period in our analyses to
account for the likelihood that noncancer care would be logically deferred because of
pressing cancer diagnosis and treatment needs during the time period immediately before
and after cancer diagnosis.
Next, we conducted GEE analysis (logit link, unstructured correlation matrix) with cases or
controls in different care phases (eg, stage 0 to 1 CRC cases in the phase before diagnosis,
stage 2 to 3 CRC cases in the phase after initial treatment) as the independent variables and
receipt of preventive and diabetes services in each observation year as outcomes. We
adjusted for patient age and sex (when applicable) in all the models and included all other
covariates described above if they were significant predictors of our outcomes at the P ≤ .05
level. The diabetes care models also adjusted for the presence of a diabetes diagnosis (one
inpatient or 2 outpatient International Classification of Diseases, Ninth Revision, Clinical
Modification diagnosis codes) during the year before the observation year to account for
variation in diabetes disease activity among individuals. Adjusted odds ratios were
converted to relative risks using published methods.19 We used SAS 9.2 software (SAS
Institute, Inc., Cary, NC) to conduct all analyses.
Results
Study Group Characteristics
Controls were the youngest of the 3 study groups and patients with stage 2 to 3 CRC were
the oldest (Table 2). The majority of all 3 groups were women, although controls were most
likely (62.8%) and patients with stage 0 to 1 CRC least likely (53.9%) to be women. Before
diagnosis, controls had the least comorbidity (76.1%; comorbidity score, ≤0) and patients
with stage 0 to 1 CRC had the most co-morbidity (71.7%; comorbidity score, ≤0). Before
diagnosis, patients with stage 0 to 1 CRC had the greatest number of visits to noncancer care
physicians. These findings were generally consistent across the influenza, mammography,
and diabetes study subsamples, though the mammography sub-sample included only
women, and the comorbidity index was not significantly different across groups in the
diabetes subsample.
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Influenza Vaccination—Before diagnosis, patients with stage 0 to 1 CRC had
significantly higher annual influenza vaccination rates (unadjusted annual rates with
confidence intervals (CI), 50.9% [49.6% to 52.1%]) than both patients with stage 2 to 3
CRC (unadjusted annual rates with CI, 46.4% [45.4%, 47.4%]) and controls (unadjusted
annual rates with CI, 46.1% [45.7%–46.5%]) in unadjusted analysis (Table 3); they also had
higher likelihood of influenza vaccination in adjusted analyses (adjusted relative risk [aRR],
1.09; 95% CI, 1.06–1.12); aRR, 0.99; 95% CI, 0.97–1.01; aRR, 1.0 [reference group],
respectively) (Figure 2). In adjusted analysis, patients with stage 0 to 1 CRC had a higher
likelihood of influenza vaccination than controls throughout the study phases and had a
higher likelihood of influenza vaccination than patients with stage 2 to 3 CRC patients until
the survival phase (Figure 2). Patients with stage 2 to 3 CRC significantly increased their
likelihood of influenza vaccination between the phases before diagnosis and after initial
treatment, and they largely sustained these increases (Figure 2). Visits with noncancer and
cancer providers explained a substantial proportion of the higher likelihood of influenza
vaccination among cancer patients after diagnosis, though during the survival phase
significant differences in the likelihood of vaccination between both patients with stage 0 to
1 CRC and those with stage 2 to 3 CRC and controls remained (results not shown).
Mammography—Before diagnosis, patients with stage 0 to 1 CRC had the highest annual
mammography rate (41.6% [39.1%–44.1%]); patients with stage 2 to 3 CRC had a
significantly lower annual mammography rate (31.4% [29.4%–33.4%]) than both patients
with stage 0 to 1 CRC (41.6% [39.1%–44.1%]) and controls (38.6% [37.9%–39.2%]) in
unadjusted analyses (Table 3). Patients with stage 2 to 3 CRC also had a lower likelihood of
mammography (aRR, 0.81; 95% CI, 0.75–0.86) in adjusted analyses and did patients with
stage 2 to 3 CRC (aRR, 1.09; 95% CI, 1.02–1.15) and controls (aRR, 1.0 [reference group])
(Figure 2). All 3 study groups demonstrated significant increases in annual mammography
rates over the observation years (P ≤ .001 for trend tests); the group with stage 2 to 3 CRC
had a greater increase in annual mammography rates than both the control (P ≤ .001) and
stage 0 to 1 CRC (P ≤ .001) groups (Table 3). In adjusted analysis (Figure 2), the likelihood
of mammography among patients with stage 2 to 3 CRC reached that of controls in the
period after initial treatment and reached that of patients with stage 0 to 1 CRC in the
surveillance and survival phases. Adjusting for physician visits did not change these findings
(results not shown).
Diabetes Care—Before diagnosis, annual HgbA1c rates from the unadjusted analysis
were similar for the 3 study groups: stage 0 to 1 CRC, 55.9% (53.0%–58.7%); stage 2 to 3
CRC, 53.4% (51.0%–55.8%); controls, 53.7% (52.6%–54.7%); however, annual lipid
testing rates were higher among patients with stage 0 to 1 CRC (unadjusted annual rate,
57.3% [54.4%–60.2%]) compared with both controls (unadjusted annual rate, 52.6%
[51.6%–53.7%]) and patients with stage 2 to 3 CRC (unadjusted annual rate, 51.0% [48.6%–
53.4%]) (Table 3). These findings did not change in adjusted analysis (Figure 2). In
unadjusted analysis, the control group demonstrated increasing annual rates of HgbA1c and
lipid testing over the observation period (P ≤ .001; Table 3); in adjusted analysis, the
likelihood of controls receiving HgbA1c and lipid testing increased significantly during each
successive study phase (Figure 2). Like controls, the likelihood of HgbA1c testing among
patients with stage 0 to 1 CRC significantly increased during each successive study phase in
the adjusted analysis. The likelihood of HgbA1c testing among patients with stage 2 to 3
CRC significantly increased from the phase before diagnosis to the surveillance phase,
though this group lagged significantly behind controls in the phase after initial treatment.
Although patients with stage 0 to 1 CRC had a higher likelihood of lipid testing before
diagnosis, by the phase after initial treatment the likelihood of lipid testing among patients
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with stage 0 to 1 CRC fell to that of controls and remained at roughly the same level as
controls throughout subsequent phases (Figure 2). The likelihood of lipid testing among
patients with stage 2 to 3 CRC lagged behind controls in the phase after initial treatment and
behind both controls and patients with stage 0 to 1 CRC in the surveillance phase (Figure 2).
Adjusting for physician visits did not change these findings (results not shown).
Discussion
Elderly patients with stage 2 to 3 CRC demonstrated significant gains in influenza
vaccination after cancer diagnosis, with even more notable gains in mammography. These
unexpected findings refuted our hypothesis that cancer’s intensive treatment would supplant
this care. Instead, it may be that patients with stage 2 to 3 CRC, who are some of the least
likely to use these services before diagnosis, are now receiving regular care from cancer care
physicians who provide and/or advise use of these preventive services and are complying
with these recommendations. Alternately, or in addition, these patients’ noncancer care
physicians may more actively promote these services after cancer diagnosis. More frequent
physician visits only partially explained the gains in influenza vaccination and
mammography, however, suggesting that physician encouragement combined with patient
attention to preventive care contributed to this change. These findings match those of
research examining preventive testing among breast cancer survivors and controls,20 though
this study is the first to follow preventive service use from before diagnosis through 7 years
of survival.
Later-stage CRC patients did not demonstrate the same pattern in diabetes care. Despite
frequent physician visits, patients with stage 2 to 3 CRC had less consistent increases and
sometimes decreased diabetes testing compared with controls after initial treatment. Chronic
disease care is more complex, and cancer care physicians may feel less comfortable both
advising about and providing these services. Whether this lesser focus on diabetes care (and
potentially other chronic conditions) has a deleterious effect is unknown, but studies
demonstrating higher mortality among patients with co-morbid conditions in the first years
after diagnosis suggest the importance of optimal management of comorbid conditions.8,10
What strategies might improve care quality for cancer patients’ chronic conditions like
diabetes? Although cancer diagnosis and treatment may divert attention from other medical
conditions, cancer patients are well connected with the medical care system. Early on,
cancer patients receive care from cancer care physicians as well as primary care physicians
and noncancer care specialists, who may have conducted screening or initial symptom
evaluation; further out from diagnosis, cancer survivors primarily receive care from primary
care physicians and noncancer care specialists.21 Building on these physician resources to
improve the quality of cancer patients’ care is key. One important strategy is the
development of strong partnerships between patients; their primary care physicians, who are
specialists in chronic disease management; and their cancer care physicians. With strong
partnerships in place, cancer care physicians could promote the importance of continuing
primary care visits, and primary care physicians could ensure that oncologists receive
historic clinical and psychosocial information that facilitates optimal patient care. Studies
examining these partnerships emphasize communication from oncologists to primary care
physicians to improve cancer-related care but do not highlight the importance of a
bidirectional relationship or of cancer patients’ other health concerns.22–24 The Institute of
Medicine endorses a coordinated primary and specialty care approach to addressing cancer
patients’ needs, and suggests development of a survivorship care plan to facilitate optimal
care.14 Future research systematically examining the effectiveness of strategies that enhance
communication between primary and cancer care providers about cancer-related and chronic
condition care is needed.
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Neither controls nor cases uniformly received guideline-recommended preventive or
diabetes care. This finding illustrates that neither frequent patient visits nor strong physician
partnerships alone will ensure optimal preventive or chronic disease care. Continued
implementation, evaluation, and development of care improvement strategies, such as
chronic disease management models, to care for individuals with competing medical
priorities such as a cancer diagnosis is important.25
Notably, patients with stage 0 to 1 CRC used medical care differently than both patients
with stage 2 to 3 and controls, even before diagnosis. These early-stage CRC patients had
the highest comorbidity rates and the highest hospitalization and outpatient visit rates before
diagnosis. Their high annual preventive service use rates before diagnosis could be related to
greater contact with health professionals or greater health-seeking behavior, which could in
turn help explain their early-stage cancer diagnosis.
The many cancer cases in the longitudinal SEER-Medicare database made this study
possible, yet these data are limited. They cannot document true preventive service rates.
Influenza vaccination is available in many settings, including pharmacies, where patients
may pay cash rather than submit a Medicare claim, and during hospitalization, where
vaccination is bundled with other charges. In addition, this study’s annual mammography
rates, which measure the combination of annual screening or diagnostic mammography, do
not represent every two year screening mammography as was covered by the Medicare
program during the study period. Despite these deviations from true population-based
preventive service rates, comparing these services over time or between study groups is
valid.
An additional limitation is that few evidence-based chronic disease care measures are
available in Medicare claims. We chose diabetes care markers recommended by the
American Diabetes Association that were likely to be captured reliably by claims. HgbA1c,
which monitors blood glucose control, is widely used to assess quality of care but has not
been associated with improvement in outcomes such as diabetes-related mortality.26 Claims
data are also susceptible to secular coding changes. This is most obvious in the comorbidity
index, which increased over time (eg, mean comorbidity index for 70 year olds in 1993 was
0.120 and in 1999 was 0.140). Also notable is that SEER data do not record cancer
recurrence, although we censored an individual’s observation years starting with the first
year in which there was evidence of treatment for recurrence (ie, chemotherapy and
radiation administration). Because of attrition from death, the populations in each phase
differed. To explore the influence of these population differences, we repeated analyses
including only patients with at least one observation year in the survival phase and found
similar point estimates but widened confidence intervals. Lastly, the study data are limited
by their ages. Behavioral Risk Factor Surveillance System data demonstrate increases in flu
vaccination, mammography, and cholesterol testing among the general population between
the mid-1990s and late 2000s.27 However, given that there have been no major changes in
the organization of oncology or primary care services during this time period, it is likely that
the relationships between cancer diagnosis and receipt of preventive and diabetes services
found in this study persist.
Conclusion
Cancer diagnosis and treatment are consuming medical experiences. The intensity of
medical visits and side effects of treatment can be overwhelming. Although cancer care
must be of primary concern, many cancer patients have other medical conditions that
influence survival and quality of life. The intensity of cancer treatment offers opportunities
as well as risks related to the general medical care of cancer patients. Cancer diagnosis is
Baldwin et al. Page 7













associated with an increase in receipt of preventive services such as influenza vaccination
and mammography. However, the likely narrow focus on cancer during many medical visits
does not promote care for chronic medical conditions. Improvement of this care requires
additional strategies, such as strengthening partnerships between cancer patients, primary
care physicians, and cancer care physicians. Yet these strategies alone are unlikely to bring
chronic disease care to recommended levels because the relatively low annual rates of
diabetes testing among controls show that effective strategies that improve care for all
patients with chronic conditions such as diabetes are needed.
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Adjusted relative risk of influenza vaccination, mammography, and diabetes care measures
(hemoglobin A1c and lipid testing) by cancer/control status and phase. Adjusted for the
following variables: age, sex (when applicable), race ethnicity, median annual household
income in ZIP code percent of those ≥25 years old who graduated from high school in zip
code, reason for Medicare, National Cancer Institue combined comorbidity index, and
number of hospitalizations. Note that relative risk scales differ for each measure.
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Table 1
Number of Persons in Each Study Observation Year by Study Group
Total
CRC Cases
ControlsStage 0–1 Stage 2–3
Year before prediagnosis phase (year −2) 103,830 8,865 13,296 81,669
Phase before diagnosis (year −1) 103,830 8,865 13,296 81,669
Phase after initial treatment (year 1) 103,830 8,865 13,296 81,669
Surveillance phase
 Year 2 88,859 7,548 10,679 70,632
 Year 3 67,959 5,573 7,672 54,714
 Year 4 50,159 4,082 5,366 40,711
Survival phase
 Year 5 35,134 2,825 3,575 28,734
 Year 6 22,635 1,791 2,240 18,604
 Year 7 12,262 991 1,140 10,131
CRC, colorectal cancer.
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Table 2
Characteristics of Initial Study Population by Study Group
CRC Cases
Controls (n = 81,669)Stage 0–1 (n = 8,865) Stage 2–3 (n = 13,296)
Age, years*
 67–69 15.6 13.8 19.5
 70–74 29.4 27.5 32.3
 75–79 28.0 27.5 25.1
 80–89 27.1 31.2 23.1
Female* 53.9 56.6 62.8
Race/ethnicity*
 White 86.6 87.2 84.8
 Asian 3.5 3.3 3.8
 Black 6.3 6.1 6.6
 Hispanic 1.0 1.1 2.2
 Other 2.6 2.3 2.7
National Cancer Institute combined comorbidity index during the phase before diagnosis year*
 ≤0 71.7 74.7 76.1
 >0–0.5 14.6 13.5 12.4
 >0.5–1.0 8.1 7.5 7.4
 >1.0 5.6 4.4 4.1
Hospitalizations during the phase before diagnosis year†
 0 85.3 86.9 86.6
 1 11.1 10.1 10.1
 2 2.6 2.1 2.4
 3 0.8 0.6 0.6
 4 0.2 0.3 0.2
 ≥5 0.1 0.1 0.1
Annual visits to cancer care physicians (mean [SD])‡
 Phase after initial treatment* 1.4 (3.2) 4.6 (7.1) 0.3 (1.4)
 Surveillance phase* 0.7 (1.7) 1.3 (2.1) 0.3 (1.4)
 Survival phase* 0.5 (1.5) 0.8 (1.6) 0.4 (1.5)
Visits to noncancer care physicians during the phase before diagnosis year*
 ≤7 42.6 50.0 50.1
 8–15 33.0 30.2 29.2
 16–25 16.6 14.2 14.2
 >25 7.8 5.6 6.5
Reason for Medicare eligibility§
 Age ≥65 years 94.1 94.7 93.9
 Disability/end-stage renal disease 5.9 5.3 6.1
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CRC Cases
Controls (n = 81,669)Stage 0–1 (n = 8,865) Stage 2–3 (n = 13,296)
Percent of those ≥25 years old who graduated from high school in ZIP code*||
 0–50 1.7 1.7 2.1
 50–75 16.0 16.2 17.6
 75–90 54.8 54.5 52.2
 >90 27.6 27.7 28.1
Median annual household income in ZIP code*||
 ≤$30,000 8.2 8.6 10.3
 >$30,000–45,000 38.4 39.0 38.2
 >$45,000 53.4 52.4 51.5










Missing values: people ≥25 years old who graduated from high school in ZIP code (%): stage 0–1, n = 207 (2.3%); stage 2–3, n = 300 (2.3%);
controls, n = 2274 (2.8%); median annual household income in ZIP code: stage 0–1, n = 210 (2.4%); stage 2–3, n = 301 (2.3%); controls, n = 2286
(2.8%).
CRC.
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Appendix
Medicare Claim Codes for Study Variables
Variables Claim Type Medicare Claim Codes
Mammography HCPCS/CPT 76090, 76091, 76092




Lipid testing HCPCS/CPT 80061, 80062, 82465, 82470, 83700, 83705, 83715–83721, 84478
Evidence of metastatic
disease
HCPCS/CPT 36246, 36247, 47120, 47122, 47125, 47130, 47370, 47371, 47380, 47381, 47382, 76362,
76394, 76490, 36260, 47100, C2618
ICD-9-CM 197.0, 197.00, 197.04, 197.08, 197.1, 197.2, 197.3, 197.7, 197.70, 197.8, 198.3, 198.4,
198.41, 198.45, 198.48, 198.5, 198.51
ICD-9-P 50.2, 50.20, 50.21, 50.22, 50.29, 50.3, 50.30, 50.4, 50.40
Recurrence treatment
 Chemotherapy: HCPCS/CPT 96408, 96410, 96412, 96414, 96520, 96530, 96545, 96549, J9190, J0640, J9200, Q0083,
Q0084, Q0085
ICD-9-CM V58.1, E933.1, V66.2, V67.2
ICD-9-P 99.25
 Radiation therapy: HCPCS/CPT 77261–63, 77280, 77285, 77290, 77295, 77299, 77300, 77305, 77310, 77315, 77321, 77326–
8, 77331–4, 77336, 77370, 77399, 77401–17, 77419–32, 77470, 77490, 77499, 77750,
77761–3, 77776–8, 77781–4, 77789–90, 77797, 77799,
ICD-9-CM V66.1, V67.1, V58.0
ICD-9-P 92.20–92.29
Revenue center 0333
HCPCS, Healthcare Common Procedure Coding System; CPT, Current Procedural Terminology; ICD-9-CM, International Classification of
Diseases, 9th Revision, Clinical Modification; ICD-9-P, ICD-9-CM Procedure.
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